BG45 (C007B-068688)

InformationBG45 is a class IHDACinhibitor withIC50of 289 nM, 2.0 µM, 2.2 µM and >20 µM for HDAC3, HDAC1, HDAC2, and HDAC6 in cell-free assays, respectively.TargetsHDAC3 ; HDAC1 ; HDAC2 289 nM; 2 μM; 2.2 μMIn vitroBG45 causes significant cell growth inhibition and induces caspase-dependent apoptosis in a series of MM cells. In RPMI8226 cells, BG45 synergistically enhances bortezomib-induced cytotoxicity.In vivoIn mice bearing MM.1S xenograft of human MM, BG45 (50 mg/kg, i.p.) significantly inhibits MM tumor growth. When in combination with bortezomib, BG45 (50 mg/kg, i.p.) enhances bortezomib-induced cytotoxicity.Cell Research(from reference)Cell lines：MM.1S, RPMI8226, U266, H929, MM.1/u2009R, RPMI-LR5, OPM1, OPM2 and RPMI-DOX40 cells Concentrations：~30 μM Incubation Time：48 h.

Specifications and Purity: 10mM in DMSO

Molecular Formula: C11H10N4O

Molecular Weight: 214.22

PubChem CID: 16773791

Isomeric SMILES: C1=CC=C(C(=C1)N)NC(=O)C2=NC=CN=C2